Literature DB >> 1662460

Characterization and evaluation of asymptomatic primary hyperparathyroidism.

J P Bilezikian1, S J Silverberg, E Shane, M Parisien, D W Dempster.   

Abstract

Data are presented on 97 patients with primary hyperparathyroidism who constitute a representative cohort of the disease seen today. The average calcium (11.1 +/- 0.1 mg/dl; normal 8.7-10.7), phosphorus (2.8 +/- 0.1 mg/dl; normal 2.5-4.5), and parathyroid hormone level by immunoradiometric assay (119 +/- 7 pg/ml; normal 10-65) are typical of the modern presentation of primary hyperparathyroidism. Most patients were asymptomatic in that there was evidence for nephrolithiasis in only 18% and for radiologically evident bone disease in only 1% of patients. Nevertheless, when patients were evaluated with bone densitometry and with histomorphometric analysis of the bone biopsy specimen, evidence for the hyperparathyroid process could be shown in the majority of patients. Selective reduction of cortical bone and preservation of cancellous bone were apparent. Among patients with nephrolithiasis, no particular feature distinguished them from patients without nephrolithiasis. All biochemical data were similar between both stone and non-stone formers. The selective reduction in cortical bone was seen to the same extent among those with stones as among those without stones. The average 1,25-dihydroxyvitamin D level was not increased among those with stones. When the population was divided into groups with elevated or normal 1,25-dihydroxyvitamin D levels, the incidence of nephrolithiasis was unchanged. The results indicate that bone involvement can be demonstrated among most patients with asymptomatic primary hyperparathyroidism and that no pathophysiologic mechanisms are yet apparent to account for nephrolithiasis in primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662460     DOI: 10.1002/jbmr.5650061419

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  21 in total

Review 1.  Clinical spectrum of primary hyperparathyroidism.

Authors:  J P Bilezikian; S J Silverberg
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Primary hyperparathyroidism due to atypical parathyroid adenoma presenting with peroneus brevis tendon rupture.

Authors:  S Yener; A Saklamaz; T Demir; L Kebapcilar; F Bayraktar; S Canda; S Yesil
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

3.  In vitro heterogeneity of osteogenic cell populations at various equine skeletal sites.

Authors:  Laurie A McDuffee; Gail I Anderson; Glenda M Wright; Daniel A J Ryan
Journal:  Can J Vet Res       Date:  2006-10       Impact factor: 1.310

4.  Sex and age modify biochemical and skeletal manifestations of chronic hyperparathyroidism by altering target organ responses to Ca2+ and parathyroid hormone in mice.

Authors:  Zhiqiang Cheng; Nathan Liang; Tsui-Hua Chen; Alfred Li; Christian Santa Maria; Michael You; Hanson Ho; Fuqing Song; Daniel Bikle; Chialing Tu; Dolores Shoback; Wenhan Chang
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

5.  Risk factors associated to kidney stones in primary hyperparathyroidism.

Authors:  S Corbetta; A Baccarelli; A Aroldi; L Vicentini; G B Fogazzi; C Eller-Vainicher; C Ponticelli; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

6.  Multifactorial risk profile for bone fractures in primary hyperparathyroidism.

Authors:  Erik Nordenström; Johan Westerdahl; Birger Lindergård; Pia Lindblom; Anders Bergenfelz
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

Review 7.  Endocrine regulation of bone and energy metabolism in hibernating mammals.

Authors:  Alison H Doherty; Gregory L Florant; Seth W Donahue
Journal:  Integr Comp Biol       Date:  2014-02-19       Impact factor: 3.326

8.  Advances in the management of asymptomatic hyperparathyroidism.

Authors:  Maria Luisa Brandi
Journal:  F1000 Med Rep       Date:  2009-10-29

9.  Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis.

Authors:  Luca Pietrogrande
Journal:  Int J Womens Health       Date:  2010-08-09

10.  Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen.

Authors:  H Brahm; O Ljunggren; K Larsson; E Lindh; S Ljunghall
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.